高级搜索
晚期Her-2受体阳性乳腺癌患者的临床特征及生存分析[J]. 肿瘤防治研究, 2012, 39(11): 1337-1340. DOI: 10.3971/j.issn.1000-8578.2012.11.014
引用本文: 晚期Her-2受体阳性乳腺癌患者的临床特征及生存分析[J]. 肿瘤防治研究, 2012, 39(11): 1337-1340. DOI: 10.3971/j.issn.1000-8578.2012.11.014
Treatment Outcomes and Clinicopathologic Characteristics of Advanced Her-2 Positive Breast Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2012, 39(11): 1337-1340. DOI: 10.3971/j.issn.1000-8578.2012.11.014
Citation: Treatment Outcomes and Clinicopathologic Characteristics of Advanced Her-2 Positive Breast Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2012, 39(11): 1337-1340. DOI: 10.3971/j.issn.1000-8578.2012.11.014

晚期Her-2受体阳性乳腺癌患者的临床特征及生存分析

Treatment Outcomes and Clinicopathologic Characteristics of Advanced Her-2 Positive Breast Cancer Patients

  • 摘要: 目的 分析晚期Her-2受体阳性乳腺癌的临床特征,探讨影响其预后的因素。方法收集本院2002年1月—2008年12月间114例晚期Her-2阳性乳腺癌患者的临床资料,回顾性研究其临床特点、生存状况及预后因素。结果114例晚期Her-2阳性乳腺癌患者中位年龄为46岁,8例为初治Ⅳ期;106例为初治Ⅰ~Ⅲ期,术后出现局部复发或远处转移。随访至2011年8月15日,死亡58例(51.0%)。单因素预后分析结果显示,复发年龄、是否绝经、复发转移后是否接受化疗及一线化疗疗效对患者的OS有显著影响(P<0.05)。Cox比例风险模型分析结果显示,复发年龄、是否接受一线化疗以及一线化疗疗效是影响晚期Her-2高表达乳腺癌预后的独立因素。结论晚期Her-2高表达乳腺癌患者早期易出现局部复发和远处转移,可能与其侵袭性较高有关。晚期Her-2高表达乳腺癌患者化疗能够改善其预后。

     

    Abstract: Objective To characterize the sites of distant recurrence and clinical outcomes in a cohort of Chinese patients with metastatic Her-2 positive breast cancer. Methods One hundred and fourteen patients with metastatic Her-2 positive breast cancer treated at Shandong Tumor Hospital from January 2002 to December 2008 were included in this study.The clinicopathologic features and long-term survival of the patients were retrospectively analyzed. Results The median age of the patients was 46 years.8 patients presented with stage Ⅳdisease,106 patients presented withⅠ- Ⅲ stage.By August 15th,2011,58 patients were died(51.0%).The median OS of patients with CR/PR was significantly longer than that of patients with SD/PD.Distant metastasis,first-line chemotherapy and clinical response were signi ficantly related with OS by univariate analysis.Furthermore,first-line chemotherapy and clinical response were demonstrated to be independent prognostic factor by multivariate analysis. Conclusion Recurrence risk and mortality are considerably higher in advanced Her-2 overexpressed breast cancer patients with the early years follow-up.Advanced Her-2 overexpressed breast cancer is aggressive clinical behavior.Our findings also suggest that chemotherapy can effectively improve the outcome of those patients.

     

/

返回文章
返回